Abstract
There are limited data regarding cycling between interleukin-17 (IL-17) inhibitors in psoriatic arthritis (PsA). We aimed to report the efficacy of an IL-17 inhibitor (ixekizumab—IXE) after inadequate response (IR) of another one (secukinumab—SEC) in patients with PsA. Case series of PsA patients who received IXE after SEC-IR in four rheumatology centers between 1/9/2021 and 1/9/2022 were included. Peripheral arthritis was assessed with disease activity in psoriatic arthritis score (DAPSA) and skin involvement with body surface area (BSA). Axial disease was defined as having both imaging and clinical features and its activity was measured with the ankylosing spondylitis disease activity score (ASDAS). Twenty-four patients (54.2% female, mean [SD] age: 51.6 [14.1]) who were SEC-IR and received IXE either immediately (n = 11) or after ≥ 1 interposed biologic disease modifying anti-rheumatic drug (bDMARD) (n = 13) were included. Patients were followed on IXE for a mean [SD] period of 9.6 [4.9] months. Among patients with peripheral arthritis (n = 24), the mean [SD] DAPSA decreased from 22.8 [8.6] to 13.6 [7.8] during follow-up (p = 0.0001) with 62.5% of patients showing improvement in the DAPSA disease activity categories. For patients with axial involvement (n = 16), a clinically meaningful improvement (Δ ≥ 1.1 in ASDAS) was noted in 50% (8/16), while dactylitis and enthesitis resolution was observed in 60% (3/5) and 83% (5/6) of patients, respectively. Regarding psoriasis, the mean [SD] BSA of involved skin decreased from 8.7 [8.7] to 2.4 [3.3] (p = 0.001). In this case series, treatment with IXE after inadequate response to another IL-17 inhibitor (SEC) was efficacious in a real-world setting in patients with PsA, including axial disease.
Data avaialbility
All data used for this study are published in this manuscirpt. Further information is available upon reasonable request to the corresponding author.
References
Gialouri C, Evangelatos G, Zhao SS et al (2022) Depression and anxiety in a real-world psoriatic arthritis longitudinal study: should we focus more on patients’ perception? Clin Exp Rheumatol. https://doi.org/10.55563/clinexprheumatol/8qxo80
Jamnitski A, Symmons D, Peters MJL, Sattar N, MciInnes I, Nurmohamed MT (2013) Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 72(2):211–216. https://doi.org/10.1136/annrheumdis-2011-201194
Fragoulis GE, Evangelatos G, Tentolouris N et al (2020) Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus. Ther Adv Musculoskelet Dis. 12:1759720. https://doi.org/10.1177/1759720X20976975
Gossec L, Baraliakos X, Kerschbaumer A et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):7001–7712. https://doi.org/10.1136/annrheumdis-2020-217159
Smolen JS, Landewé RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685–699. https://doi.org/10.1136/annrheumdis-2019-216655
Singh JA, Saag KG, Bridges SL et al (2016) 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68(1):1–26. https://doi.org/10.1002/art.39480
Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W (2017) Treatment persistence and healthcare costs among patients with rheumatoid arthritis changing biologics in the USA. Adv Ther 34(11):2422–2435. https://doi.org/10.1007/s12325-017-0617-5
Schiff MH, von Kempis J, Goldblum R, Tesser JR, Mueller RB (2014) Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann Rheum Dis 73(12):2174–2177. https://doi.org/10.1136/annrheumdis-2014-205325
Gottenberg JE, Brocq O, Perdriger A et al (2016) Non–TNF-targeted biologic vs a second anti-tnf drug to treat rheumatoid arthritis in patients with insufficient response to a first Anti-TNF Drug. JAMA 316(11):1172. https://doi.org/10.1001/jama.2016.13512
Favalli EG, Biggioggero M, Marchesoni A, Meroni PL (2014) Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology 53(9):1664–1668. https://doi.org/10.1093/rheumatology/keu158
Rubbert-Roth A, Szabó MZ, Kedves M, Nagy G, Atzeni F, Sarzi-Puttini P (2019) Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. Autoimmun Rev 18(12):102398. https://doi.org/10.1016/j.autrev.2019.102398
Merola JF, Lockshin B, Mody EA (2017) Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum 47(1):29–37. https://doi.org/10.1016/j.semarthrit.2017.02.001
Mease PJ, Karki C, Liu M et al (2019) Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. RMD Open 5(1):000880. https://doi.org/10.1136/rmdopen-2018-000880
Damiani G, Conic RRZ, de Vita V et al (2019) When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab. Dermatol Ther 32(2):12793. https://doi.org/10.1111/dth.12793
Berman J, Furer V, Berman M et al (2021) Treatment with ixekizumab following secukinumab failure in patients with psoriatic arthritis: Real-Life experience from a resistant population. Biologics 15:463–470. https://doi.org/10.2147/BTT.S326792
Darabian S, Badii M, Dutz JP, Chan J (2022) A Retrospective Study on the Effectiveness of Ixekizumab After Treatment With Secukinumab for Patients With Active Psoriatic Arthritis. J Psoriasis Psoriatic Arthritis 7(1):13–16. https://doi.org/10.1177/24755303211063841/ASSET/IMAGES/LARGE/10.1177_24755303211063841-FIG1.JPEG
Barešić M, Smiljanić Tomičević L, Anić B, Mayer M (2022) Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review. Rheumatol Int 42(2):365–370. https://doi.org/10.1007/S00296-021-05065-1/TABLES/1
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673. https://doi.org/10.1002/art.21972
Loft N, Halling AS, Egeberg A, Skov L (2021) Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis. J Am Acad Dermatol 84(1):130–138. https://doi.org/10.1016/j.jaad.2020.07.085
Sotiriou E, Bakirtzi K, Papadimitriou I et al (2022) Real-life intraclass switch among <scp>IL</scp> -17 inhibitors in psoriasis: results from a single-centre, 24-week, retrospective study. J Eur Acad Dermatology Venereol 36(11):e952–e953. https://doi.org/10.1111/jdv.18381
Jadon DR, Sengupta R, Nightingale A et al (2017) Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis 76(4):701–707. https://doi.org/10.1136/annrheumdis-2016-209853
Lopez-Medina C, Ziade N (2022) Axial Disease in Psoriatic Arthritis: how can we Define it, and does it have an Impact on Treatment? Mediterr J Rheumatol 33(1):142. https://doi.org/10.31138/mjr.33.1.142
Baraliakos X, Gossec L, Pournara E et al (2021) Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis 80(5):582–590. https://doi.org/10.1136/annrheumdis-2020-218808
Cantini F, Niccoli L, Nannini C et al (2017) Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum 47(2):183–192. https://doi.org/10.1016/j.semarthrit.2017.03.008
Ariani A, Santilli D, Mozzani F et al (2021) Cycling or swap biologics and small molecules in psoriatic arthritis. Medicine (Baltimore) 100(16):25300. https://doi.org/10.1097/MD.0000000000025300
Paul C (2018) Ixekizumab or secukinumab in psoriasis: what difference does it make? Br J Dermatol 178(5):1003–1005. https://doi.org/10.1111/BJD.16497
Funding
No specific funding received.
Author information
Authors and Affiliations
Contributions
Conception and design: GEF, AP, and CK. Data collection: all authors. Data analysis: AP, GEF, and CK. Data interpretation: AP, GEF, and CK. Drafting manuscript: AP, CK, and NK. Revising manuscript: all authors. Final approval of the version to be published: all authors. Agreement to be accountable for all aspects of the work: all authors.
Corresponding author
Ethics declarations
Conflict of interest
A. Panagiotopoulos, speaker fees/honoraria: none, C. Koutsianas, speaker fees/honoraria: Abbvie, Pfizer, UCB, Novartis, Aenorasis, Eli-Lilly, Genesis—Pharma, N. Kougkas, speaker fees/honoraria: Abbvie, Pfizer, UCB, Novartis, Aenorasis, UCB, Eli-Lilly, Roche, Genesis, Viatris, MSD, D. Moschou, speaker fees/honoraria: none, V-K Bournia, speaker fees/honoraria: Abbvie, Vianex, S. Gazi, speaker fees/honoraria: none, M.G Tektonidou, speaker fees/honoraria: Genesis—Pharma, UCB, GlaxoSmithKline, MSD, Novartis, Faran, D. Vassilopoulos, speaker fees/honoraria: Abbvie, Aenorasis, Amgen, Boehringer Ingelheim, Janssen, Genesis—Pharma, GSK, MSD, Pfizer, Roche, Sobi, UCB, Eli-Lilly, P.P Sfikakis, speaker fees/honoraria: Actelion, Pfizer, Genesis—Pharma, MSD, UCB, Boehringer Ingelheim, Aenorasis, Gilead, Abbvie, Novartis, Eli-Lilly, G.E Fragoulis, speaker fees/honoraria: Abbvie, Pfizer, UCB, Novartis, Aenorasis, UCB, Janssen, Eli-Lilly.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Panagiotopoulos, A., Koutsianas, C., Kougkas, N. et al. Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease. Rheumatol Int 43, 969–973 (2023). https://doi.org/10.1007/s00296-023-05289-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-023-05289-3